# US 2025/0154115 A1 · Arylbenzoisoxazole compounds as ip6k and ipmk inhibitors and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154115 A1
- Document ID: US20250154115A1
- Status: Published application
- Kind: A1
- Application number: 18/835,870
- Filed: 2023-02-10
- Published: 2025-05-15
- Earliest claimed: 2022-02-11
- Applicants: The University of North Carolina At Chapel Hill
- Inventors: Xiaodong Wang; Yubai Zhou
- Web page: https://patentgrep.com/patent/US20250154115A1

## CPC

- C07D 261/20: condensed with carbocyclic rings or ring systems
- A61K 31/423: condensed with carbocyclic rings
- A61K 31/4245: Oxadiazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Arylbenzoisoxazole compounds of Formula II, where R1 and R2 are defined herein, are useful for inhibiting isoforms of IP6K and IPMK, and for treating diseases and disorders such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), cancer, and viral infections. Methods of using compounds of Formula II for prevention or treatment of such diseases and disorders, pharmaceutical compositions comprising the compounds, and methods of preparing the compounds are also disclosed.

## Claims

### Claim 1

A compound of Formula II:
or a pharmaceutically acceptable salt thereof, wherein
X is aryl or heteroaryl;
R3 is, in each instance, selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, -D, —OH, —OR5, —NH—COR6, —CONR7R8, —SO2—NHR9, and NR10R11
p is an integer from 0 to 5;
Y is present or absent, and when present selected from the group consisting of alkyl, cycloalkyl, and alkenyl; and
R4 is selected from the group consisting of —CO2H, —CO2R5, —CONR7R8, —SO2—NHR6, —SO3H, —P(O)(OH)(OR9), heteroaryl, and heterocycloalkyl; wherein
R5 is selected from alkyl, aryl, heteroaryl, and heterocycloalkyl; R6 is selected from alkyl, cycloalkyl, aryl, and heteroaryl; R7 and R8 are each independently selected from hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; R9 is selected from alkyl, aryl, heteroaryl, and heterocycloalkyl; and R10 and R11 are each independently selected from hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Y is absent.

### Claim 3 (depends on 2)

The compound of claim 2, wherein R4 is selected from the group consisting of —CO2H, —CONR7R8, heteroaryl, and heterocycloalkyl.

### Claim 4 (depends on 3)

The compound of claim 3, wherein R4 is selected from the group consisting of

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 4)

The compound of claim 4, wherein X is aryl.

### Claim 9 (depends on 1)

The compound of claim 1, wherein the compound is selected from a compound of Formula III, IV, and V:

### Claim 10 (depends on 9)

The compound of claim 9, wherein R3 is aryl or halo.

### Claim 11 (depends on 9)

The compound of claim 9, wherein p is 1 and R3 is selected from —OR5, NH—COR6, alkyl, aryl, heteroaryl, and heterocycloalkyl, wherein R6 is alkyl, cycloalkyl or heterocycloalkyl.

### Claim 12

(canceled)

### Claim 13 (depends on 11)

The compound of claim 11, wherein the heterocycloalkyl is piperidinyl.

### Claim 14

(canceled)

### Claim 15 (depends on 11)

The compound of claim 11, wherein R5 is heteroaryl or heterocycloalkyl.

### Claim 16 (depends on 15)

The compound of claim 15, wherein R5 is pyridinyl or piperdinyl.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

A compound having one of the following structures:

### Claim 20 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carrier or excipient.

### Claim 21 (depends on 1)

A method of preventing or treating a disease or disorder mediated by IP6K and/or IPMK, the method comprising administering a therapeutically effective amount of a compound of claim 1 to a subject in need thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein the disease or disorder is selected from obesity, obesity related diseases, hyperphosphataemia, cancer, fungi infections, parasitic infections, and viral infections.

### Claim 23 (depends on 22)

The method of claim 22, wherein the obesity related diseases are non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).

### Claim 24 (depends on 22)

The method of claim 22, wherein the cancer is glioblastoma and the viral infection is corona virus.

### Claim 25

(canceled)

### Claim 26 (depends on 22)

The method of claim 22, wherein the disorder is hyperphosphataemia.

### Claim 27 (depends on 22)

The method of claim 22, wherein the fungi infection is caused by a yeast strain selected from Cryptococcus neoformans and Candida albicans and the parasitic infection is caused by parasite Toxoplasma gondii.

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30 (depends on 1)

A kit for treating a disease or disorder mediated by IP6K and/or IPMK, the kit comprising: 1) a pharmaceutical composition comprising a compound of Formula II from claim 1, and 2) instructions for use.

### Claim 31

(canceled)
